SpectraCure AB (publ) (SPEC.ST)

2.9500 +0.2600 (+9.67%) At close: 05:29PM CEST

SpectraCure AB (publ)

Gasverksgatan 1
Lund 222 29
Sweden
46 46 16 20 70
https://www.spectracure.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 16

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Masoud Khayyami Ph.D.	Interim CEO & Director	300k	N/A	1963
Mr. Henrik Ljung	Chief Financial Officer	N/A	N/A	1958
Dr. Johannes Swartling Ph.D.	Chief Technology Officer	N/A	N/A	1972
Ms. Mirjam Johansson	Administrative Manager	N/A	N/A	N/A
Ms. Kristina Holst	Head of Clinical Affairs	N/A	N/A	1967

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

SpectraCure AB (publ) engages in the development of cancer treatment system. It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer. The company was incorporated in 2003 and is based in Lund, Sweden.

Corporate governance

SpectraCure AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.